Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01554800 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease
Atherosclerosis

Interventions

DRUG: ACP-501

Sponsor

MedImmune LLC

Collaborators

[object Object]